The purpose of this EAP is to provide bezuclastinib to patients with a diagnosis of Advanced Systemic Mastocytosis (AdvSM) or Nonadvanced Systemic Mastocytosis (NonAdvSM) who have received and failed or been intolerant to at least one standard approved therapy and/or have no comparable or satisfactory alternative therapy options. Both AdvSM and NonAdvSM happen when the body produces too many mast cells primarily due to a change in the KIT gene. Bezuclastinib, the investigational medicinal product offered in this EAP, is designed to work specifically against this change in the KIT gene and reduce the number of abnormal mast cells.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic. Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

Multicenter phase 2 trial utilizing oral iberdomide and subcutaneous daratumumab for up to 24 months in patients with multiple myeloma who are not minimal residual disease negative after induction therapy and autologous stem cell transplant. Research study involving the combination of daratumumab SC and iberdomide with participants who have multiple myeloma which is still detectable after induction therapy (the first line of treatment for disease) and then an autologous stem cell transplant (ASCT), which uses healthy blood stem cells from their own body to replace their diseased or damaged bone marrow after the use of high dose chemotherapy.Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

The goal of this study is to test, in the lab, whether a new treatment may improve cancer killing and bone health in patients with multiple myeloma. Newly diagnosed patients with Multiple Myeloma will meet with PI and/or study staff (face-to-face) and given information about the study. Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

This study tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period of time during which the cancer could not be detected (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing damaged DNA. In 2-3% of endometrial cancers this may be due to a hereditary condition resulted from gene mutation called Lynch Syndrome (previously called hereditary nonpolyposis colorectal cancer or HNPCC). MMR deficient cells usually have many DNA mutations. Tumors that have evidence of mismatch repair deficiency tend to be more sensitive to immunotherapy. There is some evidence that nivolumab with ipilimumab can shrink or stabilize cancers with deficient mismatch repair system. However, it is not known whether this will happen in endometrial cancer; therefore, this study is designed to answer that question. Monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving nivolumab in combination with ipilimumab may be better than nivolumab alone in treating dMMR recurrent endometrial carcinoma. Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

To evaluate the ability of urinary trypsinogen-2 to identify post pancreatectomy acute pancreatitis during the operative and immediate postoperative period. Earlier identification of PPAP will allow for close monitoring and possible early intervention for these patient's during their post operative recovery.Patients will be recruited from the patient group undergoing pancreatectomy at IU University hospital. These patient's will be prospectively identified by reviewing the schedule of Dr. Nicholas Zyromski. All patients undergoing pancreatectomy will be offered the chance to enroll in the study. Patients will not be specifically selected for or against. These patients will be contacted the morning of their surgery at University hospital in the pre-Operative area. A discussion of the goals of the project, what it entails for the patients, and any risks for the patient will be completed.THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632